The life sciences industry is arguably the most dynamic sector of the U.S. economy, with the pace of change and innovation in the industry felt globally. Bilzin Sumberg has its fingers on the pulse of this diverse and critical field. The firm's attorneys have represented pharmaceutical, medical device and diagnostics companies, and biotech companies, among others, helping them to navigate the complex business and legal issues they face as they bring life-changing products to market.

The firm's counsel has been sought for conducting securities offerings (both public and private), and mergers, acquisitions and dispositions of life sciences companies and product lines, as well as for negotiating and documenting commercialization transactions on behalf of those companies. Such transactions include supply, manufacturing, licensing, and distribution agreements with inventors of technology and intellectual property, external suppliers and original equipment manufacturers, and global distribution networks; joint venture and strategic alliance agreements between the firm's clients and other industry participants; and clinical trials, educational grant, consulting, and fellowship agreements between firm clients and research institutions, and health care providers.

Bilzin Sumberg also advises its life sciences clients on corporate governance matters, financing and day-to-day operations, periodic securities reporting and compliance, and their real estate needs. The firm's life sciences clients come of all stages of the corporate life cycle, from start-up and development-stage to growth and consolidation to exit strategies.

David M. Seifer
Practice Group Leader, Corporate & Finance
Adrian K. Felix
Alexandra Haller
Jeffrey I. Snyder
General Counsel, Head of Bankruptcy, CMBS Litigation and Workouts